San Diego, CA -- (SBWIRE) -- 04/07/2017 -- A deadline is coming up on April 17, 2017 in the lawsuit filed for investors of Anthera Pharmaceuticals Inc (NASDAQ:ANTH over alleged securities laws violations by Anthera Pharmaceuticals Inc.

Investors who purchased shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) have certain options and there are strict and short deadlines running. Deadline: April 17, 2017. NASDAQ:ANTH stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

According to the complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges on behalf of certain purchasers of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) common shares, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that Anthera Pharmaceuticals Inc made materially false and/or misleading statements concerning the potential efficacy and success of its Solution Study and CHABLIS-SC1 clinical trials, as the Company failed to disclose that patients were not improving in the CHABLIS-SC1 clinical trial, and that there were dosing problems inherent in the Solution Study design that created challenges to obtaining responses.

Hayward, CA based Anthera Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune disease. Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) reached in 2015 as high as $10.91 per share.

On November 10, 2016, Anthera Pharmaceuticals Inc announced that "the CHABLIS-SC1 clinical trial with blisibimod for the treatment of systemic lupus erythematosus (SLE) failed to meet its primary endpoint based upon the SLE Responder Index-6 (SRI-6) at 52 weeks."

On December 27, 2016, Anthera Pharmaceuticals Inc announced that its SOLUTION Phase 3 Study for liprotamase also failed to meet its primary endpoint. The Company announced it would conduct a new study of liprotamase.

Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) declined to as low as $0.64 per share on December 30, 2016.

Those who purchased shares of Anthera Pharmaceuticals Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com